REFERENCES
1. Tallan HH, Jones ME, Fruton JS. On the proteolytic enzymes of animal tissues. X. beef spleen cathepsin C. J Biol Chem 1952;194:793-805.
2. Rawlings ND, Barrett AJ, Thomas PD, Huang X, Bateman A, Finn RD. The MEROPS database of proteolytic enzymes, their substrates and inhibitors in 2017 and a comparison with peptidases in the PANTHER database. Nucleic Acids Res 2018;46:D624-32.
3. Novinec M, Lenarčič B. Papain-like peptidases: structure, function, and evolution. Biomol Concepts 2013;4:287-308.
5. Wu C, Jin X, Tsueng G, Afrasiabi C, Su AI. BioGPS: building your own mash-up of gene annotations and expression profiles. Nucleic Acids Res 2016;44:D313-6.
6. Korkmaz B, Caughey GH, Chapple I, et al. Therapeutic targeting of cathepsin C: from pathophysiology to treatment. Pharmacol Ther 2018;190:202-36.
7. Chalmers JD, Usansky H, Rubino CM, et al. Pharmacokinetic/pharmacodynamic evaluation of the dipeptidyl peptidase 1 inhibitor brensocatib for non-cystic fibrosis bronchiectasis. Clin Pharmacokinet 2022;61:1457-69.
8. Nakano A, Nomura K, Nakano H, et al. Papillon-Lefèvre syndrome: mutations and polymorphisms in the cathepsin C gene. J Invest Dermatol 2001;116:339-43.
9. Hart TC, Hart PS, Bowden DW, et al. Mutations of the cathepsin C gene are responsible for Papillon-Lefèvre syndrome. J Med Genet 1999;36:881-7.
10. Hart TC, Hart PS, Michalec MD, et al. Haim-munk syndrome and papillon-Lefèvre syndrome are allelic mutations in cathepsin C. J Med Genet 2000;37:88-94.
11. Sreeramulu B, Shyam ND, Ajay P, Suman P. Papillon-Lefèvre syndrome: clinical presentation and management options. Clin Cosmet Investig Dent 2015;7:75-81.
12. Turk V, Stoka V, Vasiljeva O, et al. Cysteine cathepsins: from structure, function and regulation to new frontiers. Biochim Biophys Acta 2012;1824:68-88.
13. Turk D, Janjic V, Stern I, et al. Structure of human dipeptidyl peptidase I (cathepsin C): exclusion domain added to an endopeptidase framework creates the machine for activation of granular serine proteases. EMBO J 2001;20:6570-82.
14. Cigic B, Pain RH. Location of the binding site for chloride ion activation of cathepsin C. Eur J Biochem 1999;264:944-51.
15. Lindley H. The specificity of dipeptidyl aminopeptidase I (cathepsin C) and its use in peptide sequence studies. Biochem J 1972;126:683-5.
16. Wang F, Krai P, Deu E, et al. Biochemical characterization of plasmodium falciparum dipeptidyl aminopeptidase 1. Mol Biochem Parasitol 2011;175:10-20.
17. de Vries LE, Sanchez MI, Groborz K, et al. Characterization of P. falciparum dipeptidyl aminopeptidase 3 specificity identifies differences in amino acid preferences between peptide-based substrates and covalent inhibitors. FEBS J 2019;286:3998-4023.
18. Poreba M, Mihelic M, Krai P, et al. Unnatural amino acids increase activity and specificity of synthetic substrates for human and malarial cathepsin C. Amino Acids 2014;46:931-43.
19. Łęgowska M, Hamon Y, Wojtysiak A, et al. Development of the first internally-quenched fluorescent substrates of human cathepsin C: the application in the enzyme detection in biological samples. Arch Biochem Biophys 2016;612:91-102.
20. Metrione RM, MacGeorge NL. The mechanism of action of dipeptidyl aminopeptidase. Inhibition by amino acid derivatives and amines; activation by aromatic compounds. Biochemistry 1975;14:5249-52.
21. Mcdonald JK, Callahan PX, Zeitman BB, Ellis S. Inactivation and degradation of glucagon by dipeptidyl aminopeptidase I (Cathepsin C) of rat liver. J Biol Chem 1969;244:6199-208.
22. Dolenc I, Turk B, Pungercic G, Ritonja A, Turk V. Oligomeric structure and substrate induced inhibition of human cathepsin C. J Biol Chem 1995;270:21626-31.
24. Nilsson KK, Fruton JS. Polymerization reactions catalyzed by intracellular proteinases. iv. factors influencing the polymerization of dipeptide amides by cathepsin C. Biochemistry 1964;3:1220-4.
25. Gittel C, Schmidtchen FP. Directed N-terminal elongation of unprotected peptides catalyzed by cathepsin c in water. Bioconjug Chem 1995;6:70-6.
26. Tavano OL. Protein hydrolysis using proteases: an important tool for food biotechnology. J Mol Catal B-Enzym 2013;90:1-11.
27. Cigić B, Dahl SW, Pain RH. The residual pro-part of cathepsin C fulfills the criteria required for an intramolecular chaperone in folding and stabilizing the human proenzyme. Biochemistry 2000;39:12382-90.
28. Dahl SW, Halkier T, Lauritzen C, et al. Human recombinant pro-dipeptidyl peptidase I (cathepsin C) can be activated by cathepsins L and S but not by autocatalytic processing. Biochemistry 2001;40:1671-8.
29. Lamort AS, Hamon Y, Czaplewski C, et al. Processing and maturation of cathepsin C zymogen: a biochemical and molecular modeling analysis. Int J Mol Sci 2019;20:4747.
30. Santilman V, Jadot M, Mainferme F. Importance of the propeptide in the biosynthetic maturation of rat cathepsin C. Eur J Cell Biol 2002;81:654-63.
31. Rebernik M, Snoj T, Klemenčič M, Novinec M. Interplay between tetrameric structure, enzymatic activity and allosteric regulation of human dipeptidyl-peptidase I. Arch Biochem Biophys 2019;675:108121.
32. Lauritzen C, Pedersen J, Madsen MT, Justesen J, Martensen PM, Dahl SW. Active recombinant rat dipeptidyl aminopeptidase I (cathepsin C) produced using the baculovirus expression system. Protein Expr Purif 1998;14:434-42.
33. Burge V, Mainferme F, Wattiaux R. Transient membrane association of the precursors of cathepsin C during their transfer into lysosomes. Biochem J 1991;275:797-800.
34. Muno D, Ishidoh K, Ueno T, Kominami E. Processing and transport of the precursor of cathepsin C during its transfer into lysosomes. Arch Biochem Biophys 1993;306:103-10.
35. Clair J, Shi GP, Sutherland RE, Chapman HA, Caughey GH, Wolters PJ. Cathepsins L and S are not required for activation of dipeptidyl peptidase I (cathepsin C) in mice. Biol Chem 2006;387:1143-6.
36. Hamon Y, Legowska M, Hervé V, et al. Neutrophilic cathepsin C is maturated by a multistep proteolytic process and secreted by activated cells during inflammatory lung diseases. J Biol Chem 2016;291:8486-99.
37. Olsen JG, Kadziola A, Lauritzen C, Pedersen J, Larsen S, Dahl SW. Tetrameric dipeptidyl peptidase I directs substrate specificity by use of the residual pro-part domain. FEBS Lett 2001;506:201-6.
38. Cigić B, Pain RH. Competitive inhibition of cathepsin C by guanidinium ions and reexamination of substrate inhibition. Biochem Biophys Res Commun 1999;258:6-10.
39. Rebernik M, Lenarčič B, Novinec M. The catalytic domain of cathepsin C (dipeptidyl-peptidase I) alone is a fully functional endoprotease. Protein Expr Purif 2019;157:21-7.
40. Wolters PJ, Laig-Webster M, Caughey GH. Dipeptidyl peptidase I cleaves matrix-associated proteins and is expressed mainly by mast cells in normal dog airways. Am J Respir Cell Mol Biol 2000;22:183-90.
41. Kuribayashi M, Yamada H, Ohmori T, Yanai M, Imoto T. Endopeptidase activity of cathepsin C, dipeptidyl aminopeptidase I, from bovine spleen. J Biochem 1993;113:441-9.
42. Pham CT. Neutrophil serine proteases: specific regulators of inflammation. Nat Rev Immunol 2006;6:541-50.
43. Perera NC, Schilling O, Kittel H, Back W, Kremmer E, Jenne DE. NSP4, an elastase-related protease in human neutrophils with arginine specificity. Proc Natl Acad Sci U S A 2012;109:6229-34.
44. Salvesen G, Enghild JJ. An unusual specificity in the activation of neutrophil serine proteinase zymogens. Biochemistry 1990;29:5304-8.
45. Wolters PJ, Pham CT, Muilenburg DJ, Ley TJ, Caughey GH. Dipeptidyl peptidase I is essential for activation of mast cell chymases, but not tryptases, in mice. J Biol Chem 2001;276:18551-6.
46. Pham CT, Ley TJ. Dipeptidyl peptidase I is required for the processing and activation of granzymes A and B
47. Freer ST, Kraut J, Robertus JD, Wright HT, Xuong NH. Chymotrypsinogen: 2.5-angstrom crystal structure, comparison with alpha-chymotrypsin, and implications for zymogen activation. Biochemistry 1970;9:1997-2009.
48. Reiling KK, Krucinski J, Miercke LJ, Raymond WW, Caughey GH, Stroud RM. Structure of human pro-chymase: a model for the activating transition of granule-associated proteases. Biochemistry 2003;42:2616-24.
49. Gullberg U, Andersson E, Garwicz D, Lindmark A, Olsson I. Biosynthesis, processing and sorting of neutrophil proteins: insight into neutrophil granule development. Eur J Haematol 1997;58:137-53.
50. Garwicz D, Lindmark A, Persson A, Gullberg U. On the role of the proform-conformation for processing and intracellular sorting of human cathepsin G. Blood 1998;92:1415-22.
51. Garwicz D, Lennartsson A, Jacobsen SE, Gullberg U, Lindmark A. Biosynthetic profiles of neutrophil serine proteases in a human bone marrow-derived cellular myeloid differentiation model. Haematologica 2005;90:38-44.
52. Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. Science 2004;303:1532-5.
53. Korkmaz B, Horwitz MS, Jenne DE, Gauthier F. Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases. Pharmacol Rev 2010;62:726-59.
54. Ruffell B, Affara NI, Cottone L, et al. Cathepsin C is a tissue-specific regulator of squamous carcinogenesis. Genes Dev 2013;27:2086-98.
55. Wolters PJ, Raymond WW, Blount JL, Caughey GH. Regulated expression, processing, and secretion of dog mast cell dipeptidyl peptidase I. J Biol Chem 1998;273:15514-20.
56. Dikov MM, Springman EB, Yeola S, Serafin WE. Processing of procarboxypeptidase A and other zymogens in murine mast cells. J Biol Chem 1994;269:25897-904.
57. Gullberg U, Lindmark A, Nilsson E, Persson A, Olsson I. Processing of human cathepsin G after transfection to the rat basophilic/mast cell tumor line RBL. J Biol Chem 1994;269:25219-25.
58. McEuen AR, Ashworth DM, Walls AF. The conversion of recombinant human mast cell prochymase to enzymatically active chymase by dipeptidyl peptidase I is inhibited by heparin and histamine. Eur J Biochem 1998;253:300-8.
59. Le QT, Min HK, Xia HZ, Fukuoka Y, Katunuma N, Schwartz LB. Promiscuous processing of human alphabeta-protryptases by cathepsins L, B, and C. J Immunol 2011;186:7136-43.
60. Le QT, Gomez G, Zhao W, et al. Processing of human protryptase in mast cells involves cathepsins L, B, and C. J Immunol 2011;187:1912-8.
61. Clair J, Pham CT, Villalta SA, Caughey GH, Wolters PJ. Mast cell dipeptidyl peptidase I mediates survival from sepsis. J Clin Invest 2004;113:628-34.
62. Jenne D, Rey C, Haefliger JA, Qiao BY, Groscurth P, Tschopp J. Identification and sequencing of cDNA clones encoding the granule-associated serine proteases granzymes D, E, and F of cytolytic T lymphocytes. Proc Natl Acad Sci U S A 1988;85:4814-8.
63. Caputo A, Garner R, Winkler U, Hudig D, Bleackley R. Activation of recombinant murine cytotoxic cell proteinase-1 requires deletion of an amino-terminal dipeptide. J Biol Chem 1993;268:17672-5.
64. Brown GR, McGuire MJ, Thiele DL. Dipeptidyl peptidase I is enriched in granules of
65. Mcguire M, Lipsky P, Thiele D. Generation of active myeloid and lymphoid granule serine proteases requires processing by the granule thiol protease dipeptidyl peptidase I. J Biol Chem 1993;268:2458-67.
66. Grossman WJ, Verbsky JW, Tollefsen BL, Kemper C, Atkinson JP, Ley TJ. Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells. Blood 2004;104:2840-8.
67. Pham CT, Thomas DA, Mercer JD, Ley TJ. Production of fully active recombinant murine granzyme B in yeast. J Biol Chem 1998;273:1629-33.
68. Alam S, Liu Q, Liu S, et al. Up-regulated cathepsin C induces macrophage M1 polarization through FAK-triggered p38 MAPK/NF-κB pathway. Exp Cell Res 2019;382:111472.
69. Dai J, Liu J, Zhang Q, et al. Cathepsin C is involved in macrophage M1 polarization via p38/MAPK pathway in sudden cardiac death. Cardiovasc Ther 2021;2021:6139732.
70. Liu Q, Zhang Y, Liu S, et al. Cathepsin C promotes microglia M1 polarization and aggravates neuroinflammation via activation of Ca2+-dependent PKC/p38MAPK/NF-κB pathway. J Neuroinflamm 2019;16:1-18.
71. Adkison AM, Kelley DG, Pham CTN, et al. Dipeptidyl peptidase I activates neutrophil-derived serine proteases and regulates the development of acute experimental arthritis find the latest version: dipeptidyl peptidase I activates neutrophil-derived serine proteases and regulates the development. J Clin Invest 2002;109:363-71.
72. Chu Y, Guo Y, Walls AF, Zhou X. The regulatory role of dipeptidyl peptidase I on the activation of immune granulocytes. Cell Biol Int 2017;41:1093-102.
73. Pagano MB, Bartoli MA, Ennis TL, et al. Critical role of dipeptidyl peptidase I in neutrophil recruitment during the development of experimental abdominal aortic aneurysms. Proc Natl Acad Sci U S A 2007;104:2855-60.
74. John DS, Aschenbach J, Krüger B, et al. Deficiency of cathepsin C ameliorates severity of acute pancreatitis by reduction of neutrophil elastase activation and cleavage of E-cadherin. J Biol Chem 2019;294:697-707.
75. Fan K, Wu X, Fan B, et al. Up-regulation of microglial cathepsin C expression and activity in lipopolysaccharide-induced neuroinflammation. J Neuroinflamm 2012;9:1-13.
76. Keir HR, Shoemark A, Dicker AJ, et al. Neutrophil extracellular traps, disease severity, and antibiotic response in bronchiectasis: an international, observational, multicohort study. Lancet Respir Med 2021;9:873-84.
77. Kim S, Nadel JA. Role of neutrophils in mucus hypersecretion in COPD and implications for therapy. Treat Respir Med 2004;3:147-59.
78. Guarino C, Hamon Y, Croix C, et al. Prolonged pharmacological inhibition of cathepsin C results in elimination of neutrophil serine proteases. Biochem Pharmacol 2017;131:52-67.
79. Sanchez Klose FP, Björnsdottir H, Dahlstrand Rudin A, et al. A rare CTSC mutation in Papillon-Lefèvre syndrome results in abolished serine protease activity and reduced NET formation but otherwise normal neutrophil function. PLoS One 2021;16:e0261724.
80. Bullón P, Castejón-Vega B, Román-Malo L, et al. Autophagic dysfunction in patients with Papillon-Lefèvre syndrome is restored by recombinant cathepsin C treatment. J Allergy Clin Immunol 2018;142:1131-1143.e7.
81. Suban D, Zajc T, Renko M, Turk B, Turk V, Dolenc I. Cathepsin C and plasma glutamate carboxypeptidase secreted from Fischer rat thyroid cells liberate thyroxin from the N-terminus of thyroglobulin. Biochimie 2012;94:719-26.
82. Bernardini F, Warburton MJ. Lysosomal degradation of cholecystokinin-(29-33)-amide in mouse brain is dependent on tripeptidyl peptidase-I: implications for the degradation and storage of peptides in classical late-infantile neuronal ceroid lipofuscinosis. Biochem J 2002;366:521-9.
83. Sleat DE, Donnelly RJ, Lackland H, et al. Association of mutations in a lysosomal protein with classical late-infantile neuronal ceroid lipofuscinosis. Science 1997;277:1802-5.
84. Kim KH, Pham CT, Sleat DE, Lobel P. Dipeptidyl-peptidase I does not functionally compensate for the loss of tripeptidyl-peptidase I in the neurodegenerative disease late-infantile neuronal ceroid lipofuscinosis. Biochem J 2008;415:225-32.
85. Zhang GP, Yue X, Li SQ. Cathepsin C interacts with TNF-α/p38 MAPK signaling pathway to promote proliferation and metastasis in hepatocellular carcinoma. Cancer Res Treat 2020;52:10-23.
86. Kim S, Lee S-I, Kim N, et al. Decursin inhibits cell growth and autophagic flux in gastric cancer via suppression of cathepsin C. Am J Cancer Res 2021;11:1304.
87. Khaket TP, Singh MP, Khan I, Bhardwaj M, Kang SC. Targeting of cathepsin C induces autophagic dysregulation that directs ER stress mediated cellular cytotoxicity in colorectal cancer cells. Cell Signal 2018;46:92-102.
88. Xiao Y, Cong M, Li J, et al. Cathepsin C promotes breast cancer lung metastasis by modulating neutrophil infiltration and neutrophil extracellular trap formation. Cancer Cell 2021;39:423-437.e7.
89. Korkmaz B, Lamort AS, Domain R, et al. Cathepsin C inhibition as a potential treatment strategy in cancer. Biochem Pharmacol 2021;194:114803.
90. Kavčič N, Butinar M, Sobotič B, et al. Intracellular cathepsin C levels determine sensitivity of cells to leucyl-leucine methyl ester-triggered apoptosis. FEBS J 2020;287:5148-66.
91. Nicklin MJ, Barrett AJ. Inhibition of cysteine proteinases and dipeptidyl peptidase I by egg-white cystatin. Biochem J 1984;223:245-53.
92. Tušar L, Usenik A, Turk B, Turk D. Mechanisms applied by protein inhibitors to inhibit cysteine proteases. Int J Mol Sci 2021;22:997.
93. Hamilton G, Colbert JD, Schuettelkopf AW, Watts C. Cystatin F is a cathepsin C-directed protease inhibitor regulated by proteolysis. EMBO J 2008;27:499-508.
94. Halfon S, Ford J, Foster J, et al. Leukocystatin, a new Class II cystatin expressed selectively by hematopoietic cells. J Biol Chem 1998;273:16400-8.
95. Božič J, Dolenc I. Feedback regulation of cathepsin C by the propeptide dipeptides of granzymes A and B. ACSi 2019;66:501-9.
96. Méthot N, Rubin J, Guay D, et al. Inhibition of the activation of multiple serine proteases with a cathepsin C inhibitor requires sustained exposure to prevent pro-enzyme processing. J Biol Chem 2007;282:20836-46.
97. Mølgaard A, Arnau J, Lauritzen C, Larsen S, Petersen G, Pedersen J. The crystal structure of human dipeptidyl peptidase I (cathepsin C) in complex with the inhibitor Gly-Phe-CHN2. Biochem J 2007;401:645-50.
98. Green GD, Shaw E. Peptidyl diazomethyl ketones are specific inactivators of thiol proteinases. J Biol Chem 1981;256:1923-8.
99. Laine DI, Busch-Petersen J. Inhibitors of cathepsin C (dipeptidyl peptidase I). Expert Opin Ther Pat 2010;20:497-506.
100. Furber M, Tiden AK, Gardiner P, et al. Cathepsin C inhibitors: property optimization and identification of a clinical candidate. J Med Chem 2014;57:2357-67.
101. Gardiner P, Wikell C, Clifton S, Shearer J, Benjamin A, Peters SA. Neutrophil maturation rate determines the effects of dipeptidyl peptidase 1 inhibition on neutrophil serine protease activity. Br J Pharmacol 2016;173:2390-401.
102. Bragg RA, Brocklehurst S, Gustafsson F, et al. Aortic binding of AZD5248: mechanistic insight and reactivity assays to support lead optimzation. Chem Res Toxicol 2015;28:1991-9.
103. Doyle K, Lönn H, Käck H, et al. Discovery of second generation reversible covalent DPP1 inhibitors leading to an oxazepane amidoacetonitrile based clinical candidate (AZD7986). J Med Chem 2016;59:9457-72.
104. Palmér R, Mäenpää J, Jauhiainen A, et al. Dipeptidyl peptidase 1 inhibitor AZD7986 induces a sustained, exposure-dependent reduction in neutrophil elastase activity in healthy subjects. Clin Pharmacol Ther 2018;104:1155-64.
105. Chalmers JD, Haworth CS, Metersky ML, et al. WILLOW Investigators. Phase 2 trial of the DPP-1 inhibitor brensocatib in bronchiectasis. N Engl J Med 2020;383:2127-37.
106. Sinha S, Rosin NL, Arora R, et al. Dexamethasone modulates immature neutrophils and interferon programming in severe COVID-19. Nat Med 2022;28:201-11.
107. Seren S, Derian L, Keleş I, et al. Proteinase release from activated neutrophils in mechanically ventilated patients with non-COVID-19 and COVID-19 pneumonia. Eur Respir J 2021;57:2003755.
108. Keir HR, Long MB, Abo-Leyah H, et al. STOP-COVID19 Investigators. Dipeptidyl peptidase-1 inhibition in patients hospitalised with COVID-19: a multicentre, double-blind, randomised, parallel-group, placebo-controlled trial. Lancet Respir Med 2022;10:1119-28.
109. Korkmaz B, Lesner A, Wysocka M, et al. Structure-based design and
110. Rehm SRT, Smirnova NF, Morrone C, et al. Premedication with a cathepsin C inhibitor alleviates early primary graft dysfunction in mouse recipients after lung transplantation. Sci Rep 2019;9:9925.
111. Miller BE, Mayer RJ, Goyal N, et al. Epithelial desquamation observed in a phase I study of an oral cathepsin C inhibitor (GSK2793660). Br J Clin Pharmacol 2017;83:2813-20.
112. Badorrek P, Diefenbach C, Kögler H, et al. Phase I characterization of the novel cathepsin C inhibitor BI 1291583. Am J Resp Crit Care 2022;205:A4777.
113. Pettersen EF, Goddard TD, Huang CC, et al. UCSF Chimera-a visualization system for exploratory research and analysis. J Comput Chem 2004;25:1605-12.
114. Shen XB, Chen X, Zhang ZY, Wu FF, Liu XH. Cathepsin C inhibitors as anti-inflammatory drug discovery: challenges and opportunities. Eur J Med Chem 2021;225:113818.
115. Chen X, Yan Y, Zhang Z, et al. Discovery and
116. Chen X, Yan Y, Du J, et al. Non-peptidyl non-covalent cathepsin C inhibitoEEr bearing a unique thiophene-substituted pyridine: design, structure-activity relationship and anti-inflammatory activity
117. Radzey H, Rethmeier M, Klimpel D, Grundhuber M, Sommerhoff CP, Schaschke N. E-64c-hydrazide: a lead structure for the development of irreversible cathepsin C inhibitors. ChemMedChem 2013;8:1314-21.
118. Zhang R, Durkin JP, Windsor WT. Azapeptides as inhibitors of the hepatitis C virus NS3 serine protease. Bioorg Med Chem Lett 2002;12:1005-8.
119. Venkatraman S, Kong J, Nimkar S, Wang QM, Aubé J, Hanzlik RP. Design, synthesis, and evaluation of azapeptides as substrates and inhibitors for human rhinovirus 3C protease. Bioorg Med Chem Lett 1999;9:577-80.
120. Verhelst SH, Witte MD, Arastu-Kapur S, Fonovic M, Bogyo M. Novel aza peptide inhibitors and active-site probes of papain-family cysteine proteases. Chembiochem 2006;7:943-50.
121. Bondebjerg J, Fuglsang H, Valeur KR, et al. Novel semicarbazide-derived inhibitors of human dipeptidyl peptidase I (hDPPI). Bioorg Med Chem 2005;13:4408-24.
122. Drąg M, Wieczerzak E, Pawełczak M, Berlicki Ł, Grzonka Z, Kafarski P. Toward very potent, non-covalent organophosphonate inhibitors of cathepsin C and related enzymes by 2-amino-1-hydroxy-alkanephosphonates dipeptides. Biochimie 2013;95:1640-9.
123. Jewgiński MP, Makowski M, Pawełczak M, et al. Synthesis of hybrid tripeptide peptidomimetics containing dehydroamino acid and aminophosphonic acid in the chain and evaluation of their activity toward cathepsin C. Chem Biodivers 2022;19:e202101019.
124. Sun H, Ren Y, Hou W, et al. Focusing on probe-modified peptides: a quick and effective method for target identification. Chem Commun 2016;52:10225-8.
125. Hou W, Sun H, Ma Y, Liu C, Zhang Z. Identification and optimization of novel cathepsin C inhibitors derived from EGFR inhibitors. J Med Chem 2019;62:5901-19.
126. Wang J, Chu Y, Zhou X. Inhibitory effect of triperygium wilfordii polyglucoside on dipeptidyl peptidase I
127. Ulčakar L, Novinec M. Inhibition of human cathepsins B and L by caffeic acid and its derivatives. Biomolecules 2020;11:31.
128. Touaibia M, Jean-François J, Doiron J. Caffeic acid, a versatile pharmacophore: an overview. Mini Rev Med Chem 2011;11:695-713.
129. Novinec M, Lenarčič B, Baici A. Probing the activity modification space of the cysteine peptidase cathepsin K with novel allosteric modifiers. PLoS One 2014;9:e106642.
130. Changeux JP, Christopoulos A. Allosteric modulation as a unifying mechanism for receptor function and regulation. Cell 2016;166:1084-102.
131. Novinec M, Korenč M, Caflisch A, Ranganathan R, Lenarčič B, Baici A. A novel allosteric mechanism in the cysteine peptidase cathepsin K discovered by computational methods. Nat Commun 2014;5:3287.
132. Panwar P, Søe K, Guido RV, Bueno RV, Delaisse JM, Brömme D. A novel approach to inhibit bone resorption: exosite inhibitors against cathepsin K. Br J Pharmacol 2016;173:396-410.
133. Sanchez MI, de Vries LE, Lehmann C, et al. Identification of plasmodium dipeptidyl aminopeptidase allosteric inhibitors by high throughput screening. PLoS One 2019;14:e0226270.
